Entera Bio (ENTX) Competitors $1.95 +0.04 (+2.09%) As of 07/3/2025 03:26 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ENTX vs. MBX, CMPX, TERN, HUMA, PRTA, HRTX, AMRN, PRME, SNDL, and AQSTShould you be buying Entera Bio stock or one of its competitors? The main competitors of Entera Bio include MBX Biosciences (MBX), Compass Therapeutics (CMPX), Terns Pharmaceuticals (TERN), Humacyte (HUMA), Prothena (PRTA), Heron Therapeutics (HRTX), Amarin (AMRN), Prime Medicine (PRME), SNDL (SNDL), and Aquestive Therapeutics (AQST). These companies are all part of the "pharmaceutical products" industry. Entera Bio vs. Its Competitors MBX Biosciences Compass Therapeutics Terns Pharmaceuticals Humacyte Prothena Heron Therapeutics Amarin Prime Medicine SNDL Aquestive Therapeutics Entera Bio (NASDAQ:ENTX) and MBX Biosciences (NYSE:MBX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, media sentiment, dividends, profitability, analyst recommendations, valuation, institutional ownership and earnings. Do analysts recommend ENTX or MBX? Entera Bio presently has a consensus price target of $10.00, indicating a potential upside of 412.82%. MBX Biosciences has a consensus price target of $37.50, indicating a potential upside of 200.60%. Given Entera Bio's higher probable upside, research analysts plainly believe Entera Bio is more favorable than MBX Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Entera Bio 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00MBX Biosciences 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media prefer ENTX or MBX? In the previous week, MBX Biosciences had 1 more articles in the media than Entera Bio. MarketBeat recorded 1 mentions for MBX Biosciences and 0 mentions for Entera Bio. MBX Biosciences' average media sentiment score of 1.91 beat Entera Bio's score of 0.00 indicating that MBX Biosciences is being referred to more favorably in the news media. Company Overall Sentiment Entera Bio Neutral MBX Biosciences Very Positive Is ENTX or MBX more profitable? MBX Biosciences has a net margin of 0.00% compared to Entera Bio's net margin of -4,525.11%. MBX Biosciences' return on equity of 0.00% beat Entera Bio's return on equity.Company Net Margins Return on Equity Return on Assets Entera Bio-4,525.11% -95.10% -82.77% MBX Biosciences N/A N/A N/A Do insiders and institutionals believe in ENTX or MBX? 14.1% of Entera Bio shares are owned by institutional investors. 10.4% of Entera Bio shares are owned by insiders. Comparatively, 52.2% of MBX Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Which has preferable earnings & valuation, ENTX or MBX? MBX Biosciences has lower revenue, but higher earnings than Entera Bio. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEntera Bio$180K492.38-$9.54M-$0.26-7.50MBX BiosciencesN/AN/AN/AN/AN/A SummaryMBX Biosciences beats Entera Bio on 7 of the 10 factors compared between the two stocks. Get Entera Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for ENTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ENTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ENTX vs. The Competition Export to ExcelMetricEntera BioMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$85.91M$2.92B$5.55B$9.05BDividend YieldN/A2.44%5.24%4.01%P/E Ratio-7.507.9419.5920.21Price / Sales492.38281.76418.25119.02Price / CashN/A42.7336.8958.10Price / Book8.487.518.035.67Net Income-$9.54M-$55.14M$3.18B$249.21M7 Day Performance2.63%4.61%2.93%3.28%1 Month Performance-2.99%4.72%3.75%5.55%1 Year Performance16.77%5.92%35.20%21.09% Entera Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ENTXEntera Bio2.6037 of 5 stars$1.95+2.1%$10.00+412.8%+18.9%$85.91M$180K-7.5020MBXMBX Biosciences3.2606 of 5 stars$11.41+6.1%$37.50+228.7%N/A$359.31MN/A0.0036CMPXCompass Therapeutics3.3886 of 5 stars$2.60+1.6%$13.13+404.8%+238.4%$354M$850K-6.3420Analyst UpgradeTERNTerns Pharmaceuticals3.9399 of 5 stars$3.73-2.6%$15.63+318.9%-38.3%$334.50MN/A-3.4240HUMAHumacyte2.3435 of 5 stars$2.09-1.4%$11.71+460.5%-60.1%$328.85M$1.57M-3.03150Positive NewsPRTAProthena3.0798 of 5 stars$6.07-0.2%$31.50+418.9%-67.8%$327.27M$135.16M-2.92130HRTXHeron Therapeutics4.0501 of 5 stars$2.07-3.3%$5.00+141.5%-21.8%$326.49M$144.29M-34.50300News CoverageAMRNAmarin0.8912 of 5 stars$16.22+3.2%$12.00-26.0%+18.0%$325.31M$228.61M-4.46360High Trading VolumePRMEPrime Medicine3.7573 of 5 stars$2.47+2.1%$10.08+308.2%-40.8%$324.30M$3.85M-1.20234Gap UpHigh Trading VolumeSNDLSNDL3.669 of 5 stars$1.21-1.6%$3.63+199.6%-34.9%$323.21M$671.81M-4.172,516News CoverageAQSTAquestive Therapeutics1.3884 of 5 stars$3.31+1.8%$10.14+206.4%+54.4%$322.82M$57.56M-5.61160News Coverage Related Companies and Tools Related Companies MBX Biosciences Competitors Compass Therapeutics Competitors Terns Pharmaceuticals Competitors Humacyte Competitors Prothena Competitors Heron Therapeutics Competitors Amarin Competitors Prime Medicine Competitors SNDL Competitors Aquestive Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ENTX) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Entera Bio Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Entera Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
